T-DXd & Brain Mets: Radiation Timing Matters

In this short clip from CHM Conversations, Dr. Paolo Tarantino discusses the concurrent administration of T-DXd with radiation for HER2-positive breast cancer patients with brain metastases. While T-DXd (trastuzumab deruxtecan) has shown remarkable efficacy both inside and outside the brain, the question of whether it should be administered alongside radiation therapy remains a critical one.

Dr. Tarantino shares commentary that from an expert opinion level, the real-world data and literature are starting to point to increased risks of radiation necrosis in the context of concurrent ADCs including T-DXd, and thus sequencing is being progressively preferred.